Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Copeptin, a surrogate marker for arginine vasopressin secretion, is positively associated with glucagon

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of metformin on plasma metabolite profile in the Copenhagen Insulin and Metformin Therapy (CIMT) trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Profiling of gut microbiota and plasma metabolites in persons with type 1 diabetes and kidney disease

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  • M. Piazza
  • N. M.J. Hanssen
  • F. Persson
  • J. L. Scheijen
  • M. P.H. van de Waarenburg
  • M. M.J. van Greevenbroek
  • P. Rossing
  • P. Hovind
  • C. D.A. Stehouwer
  • H. H. Parving
  • C. G. Schalkwijk
View graph of relations

Aim: Angiotensin receptor blockers (ARBs) reduce vascular complications in diabetes independently of blood pressure. Experimental studies suggested that ARBs may restore the detoxifying enzyme glyoxalase 1, thereby lowering dicarbonyls such as methylglyoxal. Human data on the effects of ARBs on plasma dicarbonyl levels are lacking. We investigated, in individuals with type 2 diabetes, whether irbesartan lowered plasma levels of the dicarbonyls methylglyoxal, glyoxal, 3-deoxyglucosone and their derived advanced glycation end products (AGEs), and increased d-lactate, reflecting greater methylglyoxal flux. Methods: We analysed a subset of the Irbesartan in Patients with T2D and Microalbuminuria (IRMA2) study. We measured plasma dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone, free AGEs and d-lactate using ultra-performance liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) in the treatment arm receiving 300 mg irbesartan (n = 121) and a placebo group (n = 101) at baseline and after 1 and 2 years. Effect of treatment was analysed with repeated measurements ANOVA. Results: There was a slight, but significant difference in baseline median methylglyoxal levels [placebo 1119 (907–1509) nmol/l vs. irbesartan 300 mg 1053 (820–1427) nmol/l], but no significant changes were observed in any of the plasma dicarbonyls over time in either group and there was no effect of irbesartan treatment on plasma free AGEs or d-lactate levels at either 1 or 2 years. Conclusion: Irbesartan treatment does not change plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone, free AGEs or d-lactate in type 2 diabetes. This indicates that increased dicarbonyls in type 2 diabetes are not targetable by ARBs, and other approaches to lower systemic dicarbonyls are needed in type 2 diabetes. (Clinical Trial Registry No: #NCT00317915).

Original languageEnglish
JournalDiabetic Medicine
Pages (from-to)e14405
ISSN0742-3071
DOIs
Publication statusPublished - 22 Sep 2020

Bibliographical note

© 2020 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

ID: 61155929